Clinical Trials

Clinical Trials

CLEAR SYNERGY OASIS 9

Status:Ongoing

A 2×2 factorial randomized controlled trial of CoLchicine and spironolactonE in patients with myocARdial infarction/SYNERGY Stent Registry – Organization to Assess Strategies for Ischemic Syndromes 9

HD PCI

Status:Ongoing

HD PCI is a multicenter, international, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI) for non-ST elevation acute coronary syndrome (NSTEACS) or stable angina.

COMPLETE-2

Status:Ongoing

A prospective, multi-centre randomized trial of physiology-guided versus angiography-guided non-culprit lesion complete revascularization strategies in patients with acute myocardial infarction and multi-vessel coronary artery disease who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI).

LAAOS-4

Status:Ongoing

A multi-centre, prospective, open-label, randomized controlled trial with blinded assessment of endpoints (PROBE) to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.

 

STEMI DTU

Status:Ongoing

Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI DTU Trial

ARTEMIS

Status:Ongoing

Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

ABBREVIATE

Status:Ongoing

De-Adoption βeta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a pragmaTic randomizEd  trial with blinded endpoints (ABBREVIATE) is a multi-centre vanguard project taking place within Alberta.

SONO-STEMILYSIS

Status:Ongoing

Open label, single-centre, randomized investigation of sonothrombolysis in 60 adult patients presenting with STEMI within 6 hours of the onset of clinical symptoms and receiving perfusion therapy with fibrinolysis as part of a pharmacoinvasive strategy.

STICH3C

Status:Ongoing

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NEPTUNE

Status:Ongoing

ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions (NEPTUNE)

PRACTICAL HERO

Status:Ongoing

A Randomized Trial of Heparin vs Placebo for Cardiac Catheterization Via the Trans-radial Approach

NACMI ECG

Status:Ongoing

N orth A merican C OVID-19 ST-Segment-Elevation M yocardial I nfarction (NACMI) registry: Rationale, design, and implications

Canadian INOCA Physiology Registry

Status:Ongoing

Canadian INOCA ( Ischemia with no obstructive arteries)  Physiology Registry